血清肝酶与大脑粉样性病症和认知表现的关联
Sang-Won Han1, Sang-Hwa Lee1, Jong Ho Kim2
1Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Gangwon-do, Republic of Korea.
Journal of Alzheimer's disease reports
|January 16, 2024
概括
较低的氨酸氨基转移酶 (ALT) 和较高的酸氨基转移酶与ALT的比率与粉样蛋白PET阳性和阿尔茨海默病 (AD) 诊断有关. 肝酶可能为AD提供诊断见解.
科学领域:
- 神经科学是一个神经科学.
- 肝病学 肝病学是一种肝病学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 斑块和神经纤维细胞.
- 新兴研究表明,肝脑相互作用会影响Aβ恒温.
研究的目的:
- 研究血清肝酶与大脑粉样蛋白病变之间的关联.
- 评估认知衰退患者肝酶和认知表现之间的联系.
主要方法:
- 包括1,036名患有认知能力下降,轻度认知障碍或AD痴呆症的患者.
- 评估了粉样蛋白PET,神经心理测试和肝酶 (AST,ALT等). ) 的情况.
- 使用倾向得分匹配,回归和机器学习分析.
主要成果:
- 较低的ALT和较高的AST-to-ALT比率与粉样蛋白PET阳性和AD诊断相关.
- AST-to-ALT比率与较差的记忆功能有关.
- 机器学习显示,AST-to-ALT比率改善了粉样蛋白状态分类.
结论:
- 肝功能可能与阿尔茨海默病有关.
- 肝酶显示AD诊断和治疗的潜力.
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115


